
Sagar Lonial, MD, FACP, on Why This MRD Approach Is ’Premature’ in MM
Blood Cancers Today Editor-in-Chief Sagar Lonial, MD, FACP, discusses how he approaches frontline therapy for multiple myeloma (MM), why he thinks certain approaches to minimal residual disease (MRD) in MM are “premature,” and the data that show why sustained MRD negativity is key, with host Chadi Nabhan, MD, MBA, FACP.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.